Latest Cardioprotection News

Nyrada Inc. has released compelling preclinical data showing its drug candidate Xolatryp protects mitochondrial function by reducing calcium overload in brain injury models, bolstering confidence ahead of its Phase IIa trial in acute myocardial infarction.

Race Oncology has activated its first clinical trial site in Hong Kong for the Phase 1 study of RC220 combined with doxorubicin in advanced solid tumours, marking a significant step in accelerating patient enrolment and broadening clinical data.

Algorae Pharmaceuticals reported a 62% reduction in net loss for FY2025, driven by R&D tax credits and cost efficiencies, while making significant strides in its AI drug discovery platform and therapeutic candidates.

Race Oncology Limited reported a significantly reduced loss for FY2025, driven by key clinical trial progress and strategic leadership changes. The company advances its RC220 program with promising Phase 1 dosing milestones and strengthens its governance to support future growth.

Nyrada’s Phase I clinical trial for Xolatryp™ concludes with positive safety and pharmacokinetic results, paving the way for a Phase IIa study in acute myocardial infarction patients.

Nyrada Inc. has raised $8.25 million through a strategic placement to fund its upcoming Phase IIa clinical trial of Xolatryp for acute myocardial infarction, positioning the company for a pivotal year ahead.

Nyrada reports successful completion of five cohorts in its Phase I trial of Xolatryp with no safety concerns, alongside compelling preclinical neuro- and cardioprotective data. A Phase IIa trial targeting heart attack patients is slated for early 2026.

Algorae Pharmaceuticals has advanced its AI-driven drug discovery platform into preclinical validation through a strategic collaboration with the Peter MacCallum Cancer Centre, while progressing its therapeutic pipeline and commercial leadership.

Nyrada Inc. is set to launch a Phase IIa clinical trial of Xolatryp™, aiming to reduce heart muscle damage in acute myocardial infarction patients undergoing PCI. The trial, planned for early 2026, follows promising Phase I safety results and strong preclinical cardioprotection data.

Race Oncology has safely treated the first patient with its RC220 drug alone and in combination with doxorubicin in a Phase 1 trial, while bolstering its clinical leadership and maintaining a strong cash position to fund operations through 2026.

Nyrada has successfully dosed and discharged the final participants in its Phase I trial of Xolatryp, reporting no adverse safety signals and setting the stage for Phase II development.

Nyrada has initiated the last cohort of its Phase I trial for Xolatryp, following a clean safety review of the highest dose tested so far. This step sets the stage for critical data that could shape the drug’s next development phase.